<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131036</url>
  </required_header>
  <id_info>
    <org_study_id>ML40714</org_study_id>
    <nct_id>NCT04131036</nct_id>
  </id_info>
  <brief_title>Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A</brief_title>
  <acronym>EmiMSK</acronym>
  <official_title>Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bloodworks</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bloodworks</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to study longitudinal joint and bone density changes in patients
      with severe Hemophilia A. Per current standard of care, most patients are on prophylactic
      FVIII replacement therapy intravenously several times weekly with a goal of keeping the
      trough &gt;1% FVIII. Recent phase 3 data suggest superior bleed protection with emicizumab
      prophylaxis every 1-2 weeks. It is the purpose of this study to longitudinally assess joint
      health and bone density over 3 years and to compare the effect of routine factor VIII
      prophylaxis with emicizumab prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary: This retrospective/prospective, non-randomized controlled study, whereby patients
      will be included in 1 of 2 groups depending on their current treatments as outlined below.
      Patients will be assigned to a specific group by the clinician/PI based on their current
      regimen with the intent to stay on this regimen for the next 3 years.

      Duration of Study and Subject Participation: Study subject enrollment is anticipated to occur
      over about 12 months and study duration per subject will be 3 years. Thus a total study
      duration of 4 years is anticipated.

      Intervention: By using musculoskeletal ultrasound, the investigators will measure joint
      health among participants and assess joint health changes over 3 years compared between group
      A (factor prophylaxis) vs. group B (emicizumab prophylaxis) as assessed by MSKUS at baseline
      and after 3 years. Other outcomes such as bone density, comparative assessment of joint and
      overall health status, and exploration of potential biomarkers for joint and bone health will
      also be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>joint health comparison</measure>
    <time_frame>3 years</time_frame>
    <description>Joint health changes over 3 years compared between group A (factor prophylaxis) vs. group B (emicizumab prophylaxis) as assessed by MSKUS at baseline and after 3 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone density comparison</measure>
    <time_frame>3 years</time_frame>
    <description>Bone density changes over 3 years compared between group A (factor prophylaxis) vs. group B (emicizumab prophylaxis) as assessed by DEXA scan at baseline and after 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparative assessment of joint and overall health</measure>
    <time_frame>3 years</time_frame>
    <description>Observational comparative assessment of joint and overall health status evaluated by activity level, functional assessment, pain assessment, joint examination, and adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mid-point assessment of joint health and bone density</measure>
    <time_frame>2 years</time_frame>
    <description>Observational assessment of joint health and bone density at 1 and 2 years in the different groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biomarkers for joint and bone health</measure>
    <time_frame>through completion of study, average 3 years</time_frame>
    <description>Exploration of potential biomarkers for joint and bone health.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <description>Male patients with severe Hemophilia A who use prophylaxis with IV factor VIII concentrate with intended trough &gt;1%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <description>Male patients with severe Hemophilia A who use prophylaxis with SQ emicizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>assessment of joint health and bone density</intervention_name>
    <description>We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples for biomarkers for storage in the data and sample research repository at
      Bloodworks Northwest
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male severe Hemophilia A patients at one of the several Hemophilia Treatment Center sites
        participating in this study and who meet the eligibility criteria and are interested in
        participating in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male gender

          -  Severe hemophilia A (factor VIII &lt; 1%)

          -  Age ≥ 16 year

          -  Either on prophylaxis with factor VIII or emicizumab with the intention to stay on the
             current regimen for the next 3 years

          -  Willing and able to give written informed consent/assent

          -  Willing to undergo MSKUS, DEXA scan +/- collection of blood sampling for repository
             biomarkers

          -  Willing to come in for baseline and 3 yearly visits

          -  Willing to answer phone survey for bleeding and safety every 3 months

        Exclusion Criteria:

          -  Current FVIII inhibitor of &gt; 0.6 BU

          -  Unable to take FVIII replacement

          -  Other known bleeding disorder

          -  Other rheumatologic disorder affecting joints

          -  Other known neuromotor defect (making physical exam difficult)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Kruse-Jarres, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bloodworks NW</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Kruse-Jarres, MD, MPH</last_name>
    <phone>(206) 292-6500</phone>
    <email>RebeccaKr@BloodWorksNW.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orthopedic Hemophilia Treatment Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hemophilia and Thrombosis Treatment Center, University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington Center for Bleeding Disorders at Bloodworks NW</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Kruse-Jarres, MD, MPH</last_name>
      <phone>206-292-6500</phone>
      <email>RebeccaKr@BloodWorksNW.org</email>
    </contact>
    <investigator>
      <last_name>Rebecca Kruse-Jarres, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Forsyth AL, Giangrande P, Hay CR, Kenet G, Kessler CM, Knöbl PN, Llinás A, Santagostino E, Young G. Difficult clinical challenges in haemophilia: international experiential perspectives. Haemophilia. 2012 Jul;18 Suppl 5:39-45. doi: 10.1111/j.1365-2516.2012.02887.x.</citation>
    <PMID>22757683</PMID>
  </reference>
  <reference>
    <citation>Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007 Aug 9;357(6):535-44.</citation>
    <PMID>17687129</PMID>
  </reference>
  <reference>
    <citation>Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015 Mar 26;125(13):2038-44. doi: 10.1182/blood-2015-01-528414. Epub 2015 Feb 23. Review.</citation>
    <PMID>25712992</PMID>
  </reference>
  <reference>
    <citation>Foltz V, Gandjbakhch F, Etchepare F, Rosenberg C, Tanguy ML, Rozenberg S, Bourgeois P, Fautrel B. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum. 2012 Jan;64(1):67-76. doi: 10.1002/art.33312.</citation>
    <PMID>21904998</PMID>
  </reference>
  <reference>
    <citation>McAlindon TE, Bannuru RR. Osteoarthritis: Is viscosupplementation really so unsafe for knee OA? Nat Rev Rheumatol. 2012 Nov;8(11):635-6. doi: 10.1038/nrrheum.2012.152. Epub 2012 Sep 11.</citation>
    <PMID>22964536</PMID>
  </reference>
  <reference>
    <citation>Porta F, Gargani L, Kaloudi O, Schmidt WA, Picano E, Damjanov N, Matucci-Cerinic M. The new frontiers of ultrasound in the complex world of vasculitides and scleroderma. Rheumatology (Oxford). 2012 Dec;51 Suppl 7:vii26-30. doi: 10.1093/rheumatology/kes336. Review.</citation>
    <PMID>23230091</PMID>
  </reference>
  <reference>
    <citation>Ceponis A, Wong-Sefidan I, Glass CS, von Drygalski A. Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients. Haemophilia. 2013 Sep;19(5):790-8. doi: 10.1111/hae.12175. Epub 2013 May 15.</citation>
    <PMID>23672827</PMID>
  </reference>
  <reference>
    <citation>Kidder W, Nguyen S, Larios J, Bergstrom J, Ceponis A, von Drygalski A. Point-of-care musculoskeletal ultrasound is critical for the diagnosis of hemarthroses, inflammation and soft tissue abnormalities in adult patients with painful haemophilic arthropathy. Haemophilia. 2015 Jul;21(4):530-7. doi: 10.1111/hae.12637. Epub 2015 Jan 27.</citation>
    <PMID>25623830</PMID>
  </reference>
  <reference>
    <citation>Aznar JA, Pérez-Alenda S, Jaca M, García-Dasí M, Vila C, Moret A, Querol F, Bonanad S. Home-delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A. Haemophilia. 2015 Mar;21(2):e147-50. doi: 10.1111/hae.12622. Epub 2015 Jan 27.</citation>
    <PMID>25623041</PMID>
  </reference>
  <reference>
    <citation>Martinoli C, Della Casa Alberighi O, Di Minno G, Graziano E, Molinari AC, Pasta G, Russo G, Santagostino E, Tagliaferri A, Tagliafico A, Morfini M. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost. 2013 Jun;109(6):1170-9. doi: 10.1160/TH12-11-0874. Epub 2013 Apr 4.</citation>
    <PMID>23571706</PMID>
  </reference>
  <reference>
    <citation>Paschou SA, Anagnostis P, Karras S, Annweiler C, Vakalopoulou S, Garipidou V, Goulis DG. Bone mineral density in men and children with haemophilia A and B: a systematic review and meta-analysis. Osteoporos Int. 2014 Oct;25(10):2399-407. doi: 10.1007/s00198-014-2773-7. Epub 2014 Jul 8. Review.</citation>
    <PMID>25001982</PMID>
  </reference>
  <reference>
    <citation>Kempton CL, Antoniucci DM, Rodriguez-Merchan EC. Bone health in persons with haemophilia. Haemophilia. 2015 Sep;21(5):568-77. doi: 10.1111/hae.12736. Epub 2015 Jul 14. Review.</citation>
    <PMID>26172840</PMID>
  </reference>
  <reference>
    <citation>Liel MS, Greenberg DL, Recht M, Vanek C, Klein RF, Taylor JA. Decreased bone density and bone strength in a mouse model of severe factor VIII deficiency. Br J Haematol. 2012 Jul;158(1):140-3. doi: 10.1111/j.1365-2141.2012.09101.x. Epub 2012 Apr 2.</citation>
    <PMID>22469061</PMID>
  </reference>
  <reference>
    <citation>Lau AG, Sun J, Hannah WB, Livingston EW, Heymann D, Bateman TA, Monahan PE. Joint bleeding in factor VIII deficient mice causes an acute loss of trabecular bone and calcification of joint soft tissues which is prevented with aggressive factor replacement. Haemophilia. 2014 Sep;20(5):716-22. doi: 10.1111/hae.12399. Epub 2014 Apr 8.</citation>
    <PMID>24712867</PMID>
  </reference>
  <reference>
    <citation>Boban A, Zupancic Salek S, Kastelan D, Nemet D. Quantitative ultrasound and dual energy X-ray absorptiometry in the assessment of osteoporosis in patients with haemophilia. Haemophilia. 2014 Nov;20(6):e420-2. doi: 10.1111/hae.12529.</citation>
    <PMID>25354773</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bloodworks</investigator_affiliation>
    <investigator_full_name>Rebecca Kruse-Jarres</investigator_full_name>
    <investigator_title>Director, Washington Center for Bleeding Disorders at Bloodworks Northwest</investigator_title>
  </responsible_party>
  <keyword>Hemophilia A</keyword>
  <keyword>Joint Health</keyword>
  <keyword>Bone Density</keyword>
  <keyword>Emicizumab</keyword>
  <keyword>factor VIII prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

